AstraZeneca AZN
What does AstraZeneca do?
AstraZeneca is a British-Swedish pharmaceutical group that researches, develops, manufactures, and markets prescription medicines worldwide. Its focus is on oncology, cardiovascular, renal, and metabolic diseases, respiratory and immune diseases, and rare diseases. Its portfolio includes Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Farxiga, and Symbicort, among others.
Revenue arises from the sale of patent-protected drugs to wholesalers, hospitals, pharmacies, and government healthcare systems, as well as from licensing and collaboration income. Key sales markets are the US, Europe, and China. In competition with other large companies in the sector, AstraZeneca is among the leading providers in cancer medicine. The company relies on a broad research pipeline, collaborations with partners such as Daiichi Sankyo, and targeted acquisitions to replace expiring patents with new active ingredients.
Score profile
Rank vs. Drug Manufacturers - General (18 companies). 10 = top of the group, 5 = middle. Calculated from the metrics below, without AI.
Metrics compared with the industry
On profitability and quality, AstraZeneca ranks above average in the group Drug Manufacturers - General (6.1/10). On growth, the company ranks above average in the group Drug Manufacturers - General (7.8/10). On valuation (higher = cheaper), the stock ranks in the middle in the group Drug Manufacturers - General (5.3/10). On financial strength, AstraZeneca ranks below average in the group Drug Manufacturers - General (3.2/10).
| Metric | Stock | Group median | Ranking |
|---|---|---|---|
| Forward P/E | 16.3x | 15.9x | better than 42 % |
| Trailing P/E | 26.1x | 26.9x | better than 59 % |
| PEG ratio | 1.3x | 3.3x | better than 88 % |
| EV/EBITDA | 14.7x | 13.6x | better than 36 % |
| Price/sales | 4.6x | 4.2x | better than 47 % |
| Price/book | 5.5x | 5.5x | better than 56 % |
| Revenue growth | 6.7% | 5.8% | better than 58 % |
| Earnings growth | 23.5% | -2.8% | better than 97 % |
| Gross margin | 81.8% | 74.2% | better than 86 % |
| Operating margin | 25.8% | 31.5% | better than 31 % |
| Net margin | 17.7% | 14.3% | better than 69 % |
| Return on equity | 22.6% | 20.2% | better than 58 % |
| Debt/equity | 66.3% | 105.3% | better than 64 % |
| Current ratio | 1.0x | 1.4x | better than 25 % |
| Free cash flow yield | 2.0% | 3.8% | better than 8 % |
| Dividend yield | 1.7% | 2.3% | – |
| Payout ratio | 45.4% | 63.3% | – |
| Beta | 0.15 | 0.31 | – |
Valuation: what is AstraZeneca worth?
Two valuation approaches – a discounted cash flow model and a valuation at the industry’s median multiples – give AstraZeneca a model range of 75.53 USD to 179.92 USD per share.
12 analysts, average rating “Buy”, average price target 208.07 USD (+12.8%).
The full DCF matrix, the reverse DCF (what growth the price implies) and scenarios are part of the Pro analysis.
What the business depends on
- Success depends heavily on patent-protected core products, especially in oncology.
- Approvals and market access for new active ingredients and additional indications broaden the revenue base.
- A productive research pipeline and successful collaborations secure replacements for expiring patents.
Risks
- Patent expirations and generic or biosimilar competition can significantly reduce revenue from established drugs.
- Clinical trials or approval procedures can fail and write off costly development projects.
- Price regulation, reimbursement pressure, and trade policy interventions in the main markets weigh on margins.
What to look for with AstraZeneca
The operating margin is particularly informative because it shows how profitable drug sales remain after high research and distribution costs.